<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7E833A22-66FB-41DB-BB4E-283D08AF9A6E"><gtr:id>7E833A22-66FB-41DB-BB4E-283D08AF9A6E</gtr:id><gtr:name>Janssen Research &amp; Development</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/07883787-C252-44BB-81D1-81AECF29A9A1"><gtr:id>07883787-C252-44BB-81D1-81AECF29A9A1</gtr:id><gtr:name>Diamond Light Source</gtr:name><gtr:address><gtr:line1>Diamond House</gtr:line1><gtr:line2>Harwell Science and Innovation Camp</gtr:line2><gtr:line3>Didcot</gtr:line3><gtr:line4>Oxfordshire</gtr:line4><gtr:postCode>OX11 0DE</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:department>Sch of Life Sciences</gtr:department><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7E833A22-66FB-41DB-BB4E-283D08AF9A6E"><gtr:id>7E833A22-66FB-41DB-BB4E-283D08AF9A6E</gtr:id><gtr:name>Janssen Research &amp; Development</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/07883787-C252-44BB-81D1-81AECF29A9A1"><gtr:id>07883787-C252-44BB-81D1-81AECF29A9A1</gtr:id><gtr:name>Diamond Light Source</gtr:name><gtr:address><gtr:line1>Diamond House</gtr:line1><gtr:line2>Harwell Science and Innovation Camp</gtr:line2><gtr:line3>Didcot</gtr:line3><gtr:line4>Oxfordshire</gtr:line4><gtr:postCode>OX11 0DE</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/23AD3B1B-A3F0-4E5F-B260-997BACE56FBB"><gtr:id>23AD3B1B-A3F0-4E5F-B260-997BACE56FBB</gtr:id><gtr:firstName>Louise</gtr:firstName><gtr:surname>Serpell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9FCB6054-D81D-4A69-BC9F-C729DE3D7D59"><gtr:id>9FCB6054-D81D-4A69-BC9F-C729DE3D7D59</gtr:id><gtr:firstName>Kevin</gtr:firstName><gtr:surname>Staras</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK022105%2F1"><gtr:id>9AADE9CD-38B2-4AD5-A257-08F263365D43</gtr:id><gtr:title>Abeta-mediated toxicity in Alzheimer's disease: delineating mechanisms of internalisation, cell-cell transmission and synaptic dysfunction</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K022105/1</gtr:grantReference><gtr:abstractText>Alzheimer's disease (AD) is a devastating illness that affects 1% of the population. Although some familial forms of AD exist, most Alzheimer's patients suffer from sporadic, late-onset AD, associated with ageing. The causes of Alzheimer's disease remain unclear, although it is now well-established that in brain cells (neurons), abnormal folding of small proteins (called Abeta and tau) represents a pivotal step in disease pathology. Our work aims to understand how these proteins can lead to the deterioration of neuronal function underlying the degenerative symptoms seen in Alzheimer's sufferers. To examine this we will use both artificially-grown and native networks of living neurons and recapitulate the changes occurring at the onset of AD as the target proteins change and become toxic. We will utilise state-of-the-art imaging methods to directly visualise the effects on basic neuronal function. Our research will also examine how the spread of toxic proteins between neurons might underlie the progression of the disease. A specific consequence of AD is the gradual dysfunction of synapses - the sites for neuron-to-neuron signalling - that are essential for the brain's ability to process information. We will use specialised fluorescence markers to examine synaptic signalling events and characterise the specific mechanisms which become disrupted. Finally, we will combine our fluorescence measurements with novel state-of-the-art microscopy experiments, allowing us to examine the detailed structural changes in neurons caused by misfolding proteins at high-resolution. Using this approach, we anticipate major new insights into understanding the critical cellular and molecular changes associated with Alzheimer's disease. With this knowledge, the rational design of therapeutic agents that can target these processes and alleviate or prevent disease symptoms becomes a realistic prospect.</gtr:abstractText><gtr:technicalSummary>Alzheimer's disease is characterised by the abnormal association of Abeta (Ab) peptide to form oligomeric species, with catastrophic consequences for neuronal function and survival. However, clear understanding of the mechanisms by which Ab exerts toxicity remains elusive. Specifically, it is not known how Ab is transmitted around neural networks, how it internalises/accumulates in neurons, the nature of its cellular/molecular targets, or the mechanisms which underlie its disruption of critical neuronal synaptic processes. This proposal will exploit established and novel biochemical, imaging and ultrastructural approaches in cultured and native hippocampal neurons to examine these issues, providing fundamental new insights into the toxic mechanisms of Ab action.

A key aim is to translate our recent findings from neuroblastoma cells, defining a pathway of Ab internalisation, into primary neurons. Ab will be tracked alongside cellular/organelle markers to examine endocytic processes and targeting to specific compartments, and followed by ultrastructural investigation. Ab transmission around neuronal networks will be assayed with genetically-encoded fusion constructs providing insight into the spreading of Ab pathology in Alzheimer's patients. We will also examine Ab consequences on presynaptic function - specifically dynamic properties of vesicle pools. Our pilot data indicates striking Ab-induced effects on functional pool partitioning, lateral vesicle trafficking and vesicle endocytic efficiency. Alongside culture experiments we will use an established transgenic model to explore synapse-specific presynaptic deficits in acute slice. This approach also permits a function-ultrastructure readout of recycling vesicles in native tissue, offering unique insights into Ab-induced vesicle pool re-organisation. Our findings will shed new light on pivotal steps in the pathway of Ab action, providing important potential targets for the rational development of therapeutics.</gtr:technicalSummary><gtr:potentialImpactText>This proposal aims to understand the molecular mechanisms underlying the toxicity of Abeta in Alzheimer's disease. The prevalence of Alzheimer's is growing as the ageing population increases. Therapies are available, but these slow disease progress rather than halting it. The need for more fundamental research into underlying mechanisms is highlighted by the recent withdrawal from further development of a promising therapeutic agent, Bapineuzumab. Therapeutic design is hampered by a lack of clear insight into the disease process. In this work, we aim to provide a better understanding of the underlying disease mechanisms and our long term goal is to identify key targets for rational drug design that will lead to an improvement both for society and for the individual patient.

1. Who will benefit from this research?
This research will provide a clearer understanding of the key processes involved in Alzheimer's disease. This will impact in two major ways: First, it will provide the scientific basis for potential targets for drug development; Second, it will provide a clearer knowledge regarding early changes associated with disease development and therefore contribute to the possibility of early diagnosis. If Alzheimer's disease is to be combated, it is essential that any therapeutic is provided prior to irreversible neuronal cell death. This research will provide information for pharmaceutical companies developing therapeutics agents for Alzheimer's disease and in the longer term this will impact on the health service and wider public. In the past few years, clear statements have been made regarding the priority for research into neurodegenerative diseases from the UK Government and the EU, as well as the USA. This research project is likely to inform policy makers in terms of specific investment in research into the most important targets for Alzheimer's disease.

2. How will they benefit?
In the long term, this research will contribute to the enhancement of public health by adding to understanding aimed at improving treatment for Alzheimer's disease. This research will be disseminated in peer-review journals, at international meetings and also communicated to the public via Caf&amp;eacute; Scientifique and the media. The research group has links with Pharma via collaboration with the translational drug discovery group recently established at the University of Sussex. Pharmaceutical companies will benefit from the clearer understanding of the disease process and potential targets on which to base design and development of drugs for Alzheimer's disease. Clinicians working with Alzheimer's patients will have a foundation for researching early diagnosis, since our findings will report on initial changes that occur in response to elevated toxic Abeta. The broader public will gain longer term benefits from improvements in treatments for Alzheimer's disease and this in turn will impact on the economy and wealth and health of the nation. The research may be used to produce therapeutics that slow or halt the disease progression, providing enhanced quality of life for those suffering from Alzheimer's disease and those caring for patients. This is a three year grant from which we would aim to provide the basis for targets for the development of therapeutics. The realistic expectation for the impact is that in the next 10 years, drugs may be developed based on our results.

Professional development
The work will deliver and train highly-skilled researchers, with expertise in organization, analysis, communication and scientific writing, relevant to many employment sectors. The PDRA will undertake a broad range of techniques including novel state-of-the art function-ultrastructure approaches developed in the Staras lab - skills of benefit to the wider academic and industrial communities. Both laboratories regularly provide projects for MSc and undergraduate internships and in this way training will be disseminated to the broader community.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-02-10</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-11-11</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>407893</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Diamond Light Source</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>DIAMOND Synchrotron</gtr:department><gtr:description>Diamond</gtr:description><gtr:id>83316B86-A313-4FC5-9B48-AA6212D7DBB3</gtr:id><gtr:impact>Currently the data is being analysed</gtr:impact><gtr:outcomeId>58b7a6f35c0856.06203038-1</gtr:outcomeId><gtr:partnerContribution>The collaborators at BL24 have provided equipment and training.</gtr:partnerContribution><gtr:piContribution>We have prepared neuronal cells on grids to be imaged using Cryo Soft Xray microscopy At BL24. We have collected preliminary data and these are being analysed</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration on APPSwe/Ind dox tg mice</gtr:description><gtr:id>9B796382-2BAE-42A4-9B7E-5F6BE0EC7829</gtr:id><gtr:impact>Experiments have been completed and analysis is currently being conducted and the results are being prepared for publication</gtr:impact><gtr:outcomeId>56ce1b765082e4.00320437-1</gtr:outcomeId><gtr:partnerContribution>The animals are bred in Southampton and are provided by them for the experiments at Sussex</gtr:partnerContribution><gtr:piContribution>Collaboration to use APPswe/Ind Dox animals to better understand the role of Abeta in Synaptic damage</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Janssen Research &amp; Development</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Collaboration with Janssen Pharmaceuticals</gtr:description><gtr:id>8F819F85-E6A3-4BFE-A560-51212FA26FFD</gtr:id><gtr:impact>Preliminary evidence on effects of Levetiracetam on vesicle recycling.</gtr:impact><gtr:outcomeId>56d55e861b18d6.22565564-1</gtr:outcomeId><gtr:partnerContribution>Writing of successful award of CASE studentship. Dialogue during reciprocal visits to Belgium and Sussex between teams.</gtr:partnerContribution><gtr:piContribution>BBSRC CASE studentship looking at pharmacology of synaptic vesicle recycling with Janssen as Industrial Partner.
PhD student is currently on industrial placement in Belgium.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open lab for non-scientists</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6B376C15-0B89-4A9E-ACA7-3FC6AA17B8DF</gtr:id><gtr:impact>An open lab session, showing non-scientists from the university some examples of research approaches/principles being used in our work. It included a short talk and opportunity to engage with ongoing experiments, talk to researchers etc. Very well-received.</gtr:impact><gtr:outcomeId>56d47f4f24b059.37190764</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Applicant visitors day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>510F7AE7-0F02-4BAD-9861-576C55802357</gtr:id><gtr:impact>Specialized visitor day for sixth form students and guests with firm interest in neuroscience study. Covered degree structure but also wider implications of neuroscience and some discussion of research.</gtr:impact><gtr:outcomeId>58b0719d922897.86655522</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alzheimer's society DTC public event and scientific meeting (ApoE)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3C353757-6225-4F6E-A2EB-6DCF10EF1B87</gtr:id><gtr:impact>Louise Serpell and Karen Marshall were interviewed for ITV meridian news as part of the event.</gtr:impact><gtr:outcomeId>58b7a2666174e3.72435668</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ARUK public information day, 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0EBA5F00-8B83-4B8D-ABD2-C5FC784688BD</gtr:id><gtr:impact>The Serpell group presented a small public engagement workshop about their work on Dementia at the Southampton based ARUK South network symposium.</gtr:impact><gtr:outcomeId>56ce1686cce598.31190178</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public engagement event at BEIS</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BD2AA3EB-DDFD-4838-9A64-EC526F1DEC08</gtr:id><gtr:impact>My research group and members of the Alzheimer's society DTC visited the BEIS to discuss research into Alzheimer's disease with staff. We presented activities and explained our research</gtr:impact><gtr:outcomeId>58b7a2ecc939f1.58368646</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Research Seminar (King's College London)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8FDF178B-A144-4EE3-B0E5-439FFE824341</gtr:id><gtr:impact>Invited seminar at King's College London to ~100 or more research scientists, PG and UG students.</gtr:impact><gtr:outcomeId>58b06b91a8f474.81528754</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STEM ambassador activity at St. Catherine's Catholic School for Girls</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>66BB5BC8-A43E-4BA9-8BA7-AFD7B5BAD5FC</gtr:id><gtr:impact>During her time in the lab, my postdoc, Stephanie Rey has carried out training to be a STEM (science, teaching, engineering and maths) ambassador. This activity was a talk to pupils (~13 y.o.) at St. Catherine's Catholic School for Girls, Bexley, London, UK on neuroscience, studying and a scientific career.</gtr:impact><gtr:outcomeId>58b81bd507b449.80214204</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Epsom mental health day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>87C84703-277A-479E-BC66-FE26C7307415</gtr:id><gtr:impact>Talk to members of the Public at Epsom mental health week.</gtr:impact><gtr:outcomeId>58b7a15ed82748.71739735</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk to U3A</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>AED295F2-F569-4BBE-A9F6-7BC30D593EF7</gtr:id><gtr:impact>Talk to the University of the Third Age based in Sutton, Surrey. Science branch. Over 60 attendees.</gtr:impact><gtr:outcomeId>58b7a1a2a69a92.70320784</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Participation in ARUK public information day, 2017 (Feb 1)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A41EA709-95A6-42A1-AA2C-F064D97408ED</gtr:id><gtr:impact>Workshops organised by Alzheimer's research UK network to engage public in Alzheimer's research. These are held once or twice a year and members of the public, patients and carers are invited to talk to researchers in a series of science &amp;quot;cafes&amp;quot;.</gtr:impact><gtr:outcomeId>58b7a0eeaec873.47146071</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Speaker at teachers conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9A60578F-CB88-4173-8005-24E599794001</gtr:id><gtr:impact>A talk on my research topic - under 'Hot Topics' session - primarily my current BBSRC and MRC work - communicated to teacher's in science disciplines. The aim is to motivate and excite teachers and their teaching by giving them insight into the latest-breaking approaches in research. Feedback from session was outstanding.</gtr:impact><gtr:outcomeId>56d47de02d0c43.97491807</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neuroscience talk (Sussex)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>35EF28C3-144F-4CFA-9296-EB8ACAB5A51D</gtr:id><gtr:impact>A seminar on research to neuroscience community at Sussex</gtr:impact><gtr:outcomeId>56d56077d28d91.12251550</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Potential undergraduate student and parent visit to university</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ED9EBDBC-3C0D-4061-8216-3E06BF1075CC</gtr:id><gtr:impact>Talk covering background to neuroscience, studying neuroscience, research etc. to broad audience interested in a possible future in this discipline.</gtr:impact><gtr:outcomeId>56d480895937a3.99417262</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Bright Sparks: Brighton science festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>61BAC3F3-91A3-4AE5-B4AD-5F0667BEE02D</gtr:id><gtr:impact>Louise Serpell and members of the research group spent the day at the BrightSparks event in Brighton which is part of the Brighton science festival, demonstrating our research and related activities to children and their parents.</gtr:impact><gtr:outcomeId>58b7a37ed06162.53330660</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ARUK network public  dementia day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B28432AF-0E6C-4BC6-AE03-1609BAAC8814</gtr:id><gtr:impact>We presented our work in a manner that was suitable for the broad audience and this sparked interesting discussions

This raised awareness of research into dementia in the regional area (south)</gtr:impact><gtr:outcomeId>5459f5f78d3e06.15873955</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open day visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0731B40E-C4CE-49EB-A4EF-C56E31CD0AA3</gtr:id><gtr:impact>Large-scale talk to 100+ people on broad ideas about neuroscience as a career direction. Included potential students and members of public.</gtr:impact><gtr:outcomeId>56d481d2c591b5.75538680</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alzheimer's society DTC public event and scientific meeting (ApoE)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3E817D31-F593-456A-89F7-DA25D4DC7201</gtr:id><gtr:impact>A scientific meeting was organised as part of the University of Sussex Alzheimer's society DTC and this was contributed to by members of the laboratory including Karen Marshall who is employed as a postdoc on this grant.</gtr:impact><gtr:outcomeId>58b7a209d6c7b0.73179544</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>117040</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Discovery Award</gtr:description><gtr:end>2018-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7C1BC8DE-D3EE-4E99-9D3E-C1E11D7CCCE8</gtr:id><gtr:outcomeId>58b073998ba1d2.84724332</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2056454</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>73E03FBC-E485-4CD4-9C37-A592952FA06F</gtr:id><gtr:outcomeId>58b072bedbe1c8.57370664</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>Singapore, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>TAURX/Wista funding for postdoc</gtr:description><gtr:end>2019-02-02</gtr:end><gtr:fundingOrg>TauRx Pharmaceuticals Ltd.</gtr:fundingOrg><gtr:id>D73E2B69-3B2C-4B7F-875B-03B6C8F200A4</gtr:id><gtr:outcomeId>56ce17c3980ec2.87503982</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>450000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Alzheimer's society, doctoral training centre</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Alzheimer?s Society</gtr:fundingOrg><gtr:id>B90700AC-2104-4346-849A-7FD8BE173D8E</gtr:id><gtr:outcomeId>56ce17535896f4.60562018</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed a non-assembling, non-toxic variant of Amyloid Beta for use in Alzheimer's studies</gtr:description><gtr:id>7BC50270-EA79-4880-874A-3451D1B80FC6</gtr:id><gtr:impact>This has the potential to transform the field of Abeta research, as it provides a carefully controlled method to enable the effects of Abeta to be studied</gtr:impact><gtr:outcomeId>56ce184d27dfa4.14702410</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Developed a control peptide for Abeta</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D8272B78-7159-4BAE-A2BB-090993A802EE</gtr:id><gtr:title>Distinct tau prion strains propagate in cells and mice and define different tauopathies</gtr:title><gtr:parentPublicationTitle>PRION</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/042b7e0c5eaaec0924ca8e0bb4f8ea03"><gtr:id>042b7e0c5eaaec0924ca8e0bb4f8ea03</gtr:id><gtr:otherNames>Sanders David W.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1933-6896</gtr:issn><gtr:outcomeId>56cd965ea27466.38876016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70CC3E8C-34DE-437D-9901-48D27CD149C3</gtr:id><gtr:title>Effects of A? exposure on long-term associative memory and its neuronal mechanisms in a defined neuronal network.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1e1c2ba005dd80f5fb42e8f50727c1a"><gtr:id>a1e1c2ba005dd80f5fb42e8f50727c1a</gtr:id><gtr:otherNames>Ford L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5675e56ce0c54</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5023E102-9086-4B9B-B43E-2FA97D4A96F6</gtr:id><gtr:title>Distinct tau prion strains propagate in cells and mice and define different tauopathies.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b181db016d6199f70e3e8680574ba17"><gtr:id>9b181db016d6199f70e3e8680574ba17</gtr:id><gtr:otherNames>Sanders DW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>543377e088d7e5.47052712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F5F5C95-42D2-44F7-AEDF-E51AFB1B813F</gtr:id><gtr:title>Ultrastructural readout of functional synaptic vesicle pools in hippocampal slices based on FM dye labeling and photoconversion.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93be8d28ee65c655e9ba2f3951f32d87"><gtr:id>93be8d28ee65c655e9ba2f3951f32d87</gtr:id><gtr:otherNames>Marra V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn><gtr:outcomeId>5452054a934128.62993542</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A85224A8-8A1B-46CF-B292-140ED6495F26</gtr:id><gtr:title>Synaptic vesicle pools: Principles, properties and limitations.</gtr:title><gtr:parentPublicationTitle>Experimental cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c9b1c30e9949762d5d97b6586fc73dd"><gtr:id>2c9b1c30e9949762d5d97b6586fc73dd</gtr:id><gtr:otherNames>Fowler MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-4827</gtr:issn><gtr:outcomeId>5675e1696ffd6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A653FCE0-DB13-4208-BA07-BB7E28EE5CDB</gtr:id><gtr:title>Europium as an inhibitor of Amyloid-?(1-42) induced membrane permeation.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ffbdf21ca986f78517dd5c8cd6e96a7"><gtr:id>6ffbdf21ca986f78517dd5c8cd6e96a7</gtr:id><gtr:otherNames>Williams TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>56cd92f86fb687.59594702</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBEBA33C-B1B6-4106-8F87-B1FC8D6FAA2A</gtr:id><gtr:title>A critical role for the self-assembly of Amyloid-?1-42 in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/276ab3bfebb71f1d69800a748c165d97"><gtr:id>276ab3bfebb71f1d69800a748c165d97</gtr:id><gtr:otherNames>Marshall KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>585d712f7698b6.59092091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2CF6E19-B3A3-43C0-A28C-08B7E9532C2C</gtr:id><gtr:title>Ultrastructural and functional fate of recycled vesicles in hippocampal synapses.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26bcf5ce7129f5ab03ca5d922ab1ec5d"><gtr:id>26bcf5ce7129f5ab03ca5d922ab1ec5d</gtr:id><gtr:otherNames>Rey SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5675ea871171b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C85490BB-DB8F-4D78-96DD-EF5647351ED9</gtr:id><gtr:title>Alzheimer's Disease and Cerebral Amyloid Angiopathy, Doppelgangers?</gtr:title><gtr:parentPublicationTitle>PROTEIN SCIENCE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64b3c6ee4592f09f285086ee61067702"><gtr:id>64b3c6ee4592f09f285086ee61067702</gtr:id><gtr:otherNames>Sarroukh Rabia</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn><gtr:outcomeId>56cd90ac126605.03991796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1709E09A-904D-47BD-8343-8B4BDB7D7D13</gtr:id><gtr:title>The relationship between amyloid structure and cytotoxicity.</gtr:title><gtr:parentPublicationTitle>Prion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/276ab3bfebb71f1d69800a748c165d97"><gtr:id>276ab3bfebb71f1d69800a748c165d97</gtr:id><gtr:otherNames>Marshall KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1933-6896</gtr:issn><gtr:outcomeId>543378294481c5.13120478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3019714-635F-4543-BC63-CCEC22319350</gtr:id><gtr:title>Characterization of Amyloid Cores in Prion Domains.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a82cf86527c6d075da5b33e0959fec0"><gtr:id>5a82cf86527c6d075da5b33e0959fec0</gtr:id><gtr:otherNames>Sant'Anna R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58b7a551b2e865.30361978</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71551721-10A2-4197-A1A1-A001E33E4C0A</gtr:id><gtr:title>Amyloidogenicity and toxicity of the reverse and scrambled variants of amyloid-? 1-42.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1893fdc57ff2970d85bf72741b8e7f3b"><gtr:id>1893fdc57ff2970d85bf72741b8e7f3b</gtr:id><gtr:otherNames>Vadukul DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>5a2fd67c353e96.18762667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B89816F-1A01-4DD0-B261-F285275B3C15</gtr:id><gtr:title>Dementia of the eye: the role of amyloid beta in retinal degeneration.</gtr:title><gtr:parentPublicationTitle>Eye (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c6ca671b7100bd80a192c3dccf0cd1d"><gtr:id>7c6ca671b7100bd80a192c3dccf0cd1d</gtr:id><gtr:otherNames>Ratnayaka JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0950-222X</gtr:issn><gtr:outcomeId>56cd92bc2e2034.91244711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34EB3F08-F14B-4218-8BAE-59EBCD7A7D51</gtr:id><gtr:title>Structure-dependent effects of amyloid-? on long-term memory in Lymnaea&amp;nbsp;stagnalis.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1e1c2ba005dd80f5fb42e8f50727c1a"><gtr:id>a1e1c2ba005dd80f5fb42e8f50727c1a</gtr:id><gtr:otherNames>Ford L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>5a2fd651f1c734.01724762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A77477B-DD26-4A97-B663-10F4E7DC78A4</gtr:id><gtr:title>De novo design of a biologically active amyloid.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afaec9ff3b862282314a3b6145c6a9a3"><gtr:id>afaec9ff3b862282314a3b6145c6a9a3</gtr:id><gtr:otherNames>Gallardo R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>58b7a551e15ae4.45300780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>277B85B5-AA19-4B2A-8D85-68F6F8CF1368</gtr:id><gtr:title>Stabilization of native amyloid ?-protein oligomers by Copper and Hydrogen peroxide Induced Cross-linking of Unmodified Proteins (CHICUP).</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ffbdf21ca986f78517dd5c8cd6e96a7"><gtr:id>6ffbdf21ca986f78517dd5c8cd6e96a7</gtr:id><gtr:otherNames>Williams TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>58b7a552430b68.57487789</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE97DFA6-1DCF-4789-997B-9E3EC9103FF8</gtr:id><gtr:title>Amyloid structure.</gtr:title><gtr:parentPublicationTitle>Essays in biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/033c63c174ab46df2fd2630ac066a33e"><gtr:id>033c63c174ab46df2fd2630ac066a33e</gtr:id><gtr:otherNames>Serpell L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0071-1365</gtr:issn><gtr:outcomeId>543378dc9e2d68.27859896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57CF3B87-B1F1-477A-86DE-804E93C6D62F</gtr:id><gtr:title>WALTZ-DB: a benchmark database of amyloidogenic hexapeptides.</gtr:title><gtr:parentPublicationTitle>Bioinformatics (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/231b795cfc462bd399708cd3b8484dd8"><gtr:id>231b795cfc462bd399708cd3b8484dd8</gtr:id><gtr:otherNames>Beerten J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1367-4803</gtr:issn><gtr:outcomeId>56cd92f75b87f5.63232604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54257C7F-0487-4BBB-873E-ECE044AD3FB7</gtr:id><gtr:title>A central role for dityrosine crosslinking of Amyloid-? in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7c98cf8970a3e2453f4f51dcaff8307"><gtr:id>c7c98cf8970a3e2453f4f51dcaff8307</gtr:id><gtr:otherNames>Al-Hilaly YK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2051-5960</gtr:issn><gtr:outcomeId>pm_20215_25_24351276</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K022105/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>